Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: A single center report of 29 cases

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 654-659

  Wang, Heng Xiang ^a   Yan, Hong Min ^a   Wang, Zhi Dong ^a   Xue, Mei ^a   Liu, Jing ^a   Guo, Zi Kuan ^b  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

GVHD; Haplotype; Hematopoietic stem cell transplantation; Myeloablative therapy

Indexed keywords

BASILIXIMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ENROFLOXACIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; STEROID; THYMOCYTE ANTIBODY; TUBERCULOSTATIC AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; EPILEPSY; FEMALE; FOLLOW UP; GRAFT FAILURE; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA RELAPSE; LUNG HEMORRHAGE; MALE; MYCOSIS; MYELITIS; MYELOABLATIVE CONDITIONING; NEUTROPHIL; OPTIC NERVE DISEASE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK ASSESSMENT; SCHOOL CHILD; SEPSIS; STEM CELL; T CELL DEPLETION; THROMBOCYTE; TUBERCULOSIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET COUNT; RABBITS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84857761650     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.624225     Document Type: Article

References (36)

1. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999;340:1704-1714.
2. Goldman FD, Rumelhart SL, DeAlacron P, et al. Poor outcome in children with refractory/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors. Bone Marrow Transplant 2000;25:943-948.
3. Handgretinger R, Lang P. Th e history and future prospective of haplo-identical stem cell transplantation. Cytotherapy 2008;10(5): 443-451.
4. Ji SQ, Chen HR, Wang HX, et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30:861-866.
5. Ji SQ, Chen HR, Yan HM, et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005;36:349-354.
6. Wang HX, Yan HM, Duan LN, et al. Haploidentical hematopoietic stem cell transplantation in children hematologic malignancies with G-CSF mobilized marrow grafts without T cell depletion: a single center report of 45 cases. Pediatr hematol Oncol 2009;26: 119-128.
7. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107: 3065-3073.
8. Xu LP, Luo XH, Chang YJ, et al. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/ haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Ann Hematol 2009;88(10):1015-1024.
9. Kurokawa T, Ishiyama K, Ozaki J, et al. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Int J Hematol 2010;91(4):661-669.
10. Chen XH, Zhang C, Zhang X, et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009;15:266-7317
11. Chen Y, Liu K, Xu L, et al. HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. Bone Marrow Transplant 2010;45(8):1333-1339.
12. Huang X, Liu D, Liu K, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Biol Blood Marrow Transplant 2009;15(1 Suppl):91-94.
13. Chen XH, Gao L, Zhang X, et al. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. Blood Cell Mol Dis 2009;43(1):98-104.
14. Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010;16(1 Suppl):S57-S63.
15. Wu T, Lu DP. Unmanipulated haploidentical blood and marrow transplantation: where we are. Hong Kong Med J 2009;15(3 Suppl 3): 27-30.
16. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in diff erent proportions. Transpl Immunol 2007;17(3):193-197.
17. Xu LP, Liu KY, Liu DH, et al. The inferiority of G-PB to rhG-CSFmobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 2010;45(6):985-992.
18. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997;20:1033-1037.
19. Ji S, Chen H, Wang H, et al. low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells. Chinese Med J 2001;114: 191-195.
20. Serody JS, Sparks SD, Lin Y, et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000;6:434-440.
21. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF) primeDallogeneic bone marrow: signifi cantly less graftvs- host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001;98:3186-3191.
22. Nagafuji K, Matsuo K, Teshima T, et al. Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry. Int J Hematol 2010;91(5):855-864.
23. Ciceri F, Bregni M, Peccatori J. Innovative platforms for haploidentical stem cell transplantation: the role of unmanipulated donor graft. J Cancer 2011;2:339-340.
24. Tuve S, Gayoso J, Scheid C, et al. Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia 2011;25(5): 880-883.
25. Kircher B, Lät zer K, Gastl G, et al. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 2003;134(3):426-430.
26. Chen HR, Ji SQ, Wang HX, et al. Humanized anti-CD25monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 2003;31(11):1019-1025.
27. Anasetti C, Martin PJ, Storb R, et al. Prophylaxis of graft-versushost disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 1991;7(5):375-381.
28. Zhang C, Zhang X, Chen XH, et al. Factors infl uencing engraftment in HLA-haploidentical/mismatch related transplantation with combined granulocyte-colony stimulating factor-mobilized peripheral blood and bone marrow for patients with leukemia. Transfuse Apher Sci 2011;44(3):249-255.
29. Guo M, Sun Z, Sun QY, et al. A modifi ed haploidentical nonmyeloablative transplantation without T cell depletion for highrisk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 2009;15(8):930-937.
30. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117(14):3921-3928.
31. Duan LN, Ding L, Yan HM, et al. Clinical research on reconstitution of CD4+CD25+T cells after haploidentical bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18(1):177-180.
32. Clark FJ, Gregg R, Piper K, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004;103(6):2410-2416.
33. Ukena SN, Grosse J, Mischak-Weissinger E, et al. Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells. Ann Hematol 2011;90(2):213-218.
34. Mochizuki K, Kikuta A, Ito M, et al. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children. Clin Transplant 2011;25: 892-897.
35. Wang Z, Shi BY, Qian YY, et al. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin Exp Immunol 2009;155(3): 496-503
36. Xu LP, Liu KY, Liu DH, et al. Th e inferiority of G-PB to rhGCSF- mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/ haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 2010;45(6):985-992.